English Abstract
Journal Article
Review
Add like
Add dislike
Add to saved papers

[DEVELOPMENT OF HYPOXIA-INDUCIBLE FACTOR 1α IN TISSUE ENGINEERED ANGIOGENESIS AND OSTEOGENESIS].

OBJECTIVE: To review the development and applications of hypoxia-inducible factor la (HIF-1α) in the strategy of tissue engineered angiogenesis and osteogenesis.

METHODS: The literature about HIF-1α in tissue engineering technology was reviewed, analyzed, and summarized.

RESULTS: HIF-1α plays a key role in arigiogenic-osteogenic coupling, and as an upstream regulator, HIF-1α can regulate the expressions of its target genes related with angiogenesis and osteogenesis. In addition, HIF-1α not only can control and improve the angiogenesis, but also has important significance in proliferation and differentiation of seed cells, especially stem cells, which is the foundation for bone healing.

CONCLUSION: With the development of tissue engineering technology, the problems in the applications of HIF-1α, such as the effective dose of targeting controlled-release, pro-inflammatory effect, and carcinogenicity, will be explored and solved in the future, so it can be used better in clinical.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app